Properties (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
monoclonal antibody
|
| gptkbp:activeDuring |
gptkb:guselkumab
|
| gptkbp:administrativeDivision |
once every 8 weeks after initial doses
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:clinicalTrials |
gptkb:DISCOVER-1
gptkb:DISCOVER-2 Phase 3 VOYAGE 1 VOYAGE 2 American_Academy_of_Dermatology_guidelines European_Dermatology_Forum_guidelines |
| gptkbp:contraindication |
thrombosis
active infections hypersensitivity to the drug serious infections malignancies |
| gptkbp:developedBy |
gptkb:Janssen_Pharmaceuticals
|
| gptkbp:dosageForm |
solution for injection
|
| gptkbp:drugInterdiction |
immunomodulator
linear pharmacokinetics biologic therapy inhibition of IL-23 signaling |
| gptkbp:endOfLife |
approximately 15 days
|
| gptkbp:formulation |
auto-injector
pre-filled syringe |
| gptkbp:hasPopulation |
adults
children over 6 years old |
| gptkbp:healthcare |
important for efficacy
|
| https://www.w3.org/2000/01/rdf-schema#label |
Guselkumab
|
| gptkbp:impact |
long-term treatment
|
| gptkbp:issuedBy |
subcutaneous injection
|
| gptkbp:lastProduced |
2017
|
| gptkbp:mandates |
active psoriatic arthritis
moderate to severe plaque psoriasis |
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:notableFeature |
gptkb:secukinumab
gptkb:risankizumab tildrakizumab ustekinumab |
| gptkbp:numberOfStudents |
primarily through the reticuloendothelial system
|
| gptkbp:patentExpiration |
2027
|
| gptkbp:researchFocus |
autoimmune disorders
chronic inflammatory diseases |
| gptkbp:safetyFeatures |
post-marketing surveillance
|
| gptkbp:sells |
gptkb:Tremfya
|
| gptkbp:sideEffect |
headache
injection site reactions upper respiratory infections |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
IL-23
|
| gptkbp:triggerType |
inhibits interleukin-23
|
| gptkbp:usedFor |
treatment of psoriasis
treatment of psoriatic arthritis |